Bellevue Life Sciences Acquisition Corp.

NasdaqCM:BLAC.U Stock Report

Market Cap: US$44.5m

Bellevue Life Sciences Acquisition Past Earnings Performance

Past criteria checks 0/6

Bellevue Life Sciences Acquisition has been growing earnings at an average annual rate of 57%, while the Capital Markets industry saw earnings growing at 8% annually.

Key information

57.0%

Earnings growth rate

56.0%

EPS growth rate

Capital Markets Industry Growth10.3%
Revenue growth raten/a
Return on equityn/a
Net Marginn/a
Last Earnings Update30 Jun 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Bellevue Life Sciences Acquisition makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:BLAC.U Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240020
31 Mar 240020
31 Dec 230020
30 Sep 230010
30 Jun 230010
31 Mar 230000
31 Dec 220000
30 Sep 220000
30 Jun 220000
31 Mar 220000
31 Dec 210000

Quality Earnings: BLAC.U is currently unprofitable.

Growing Profit Margin: BLAC.U is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BLAC.U is unprofitable, but has reduced losses over the past 5 years at a rate of 57% per year.

Accelerating Growth: Unable to compare BLAC.U's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BLAC.U is unprofitable, making it difficult to compare its past year earnings growth to the Capital Markets industry (18.1%).


Return on Equity

High ROE: BLAC.U's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies